Phylos closed an investment led by Organigram, that deepens the collaboration between the two companies and supports continued development of Phylos' cannabis genetics platform.
Through this investment, Organigram gains priority access to selected genetics, while Phylos continues to advance its broader breeding and development roadmap.
"Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics," said Ralph Risch, CEO of Phylos. "Their investment allows us to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale."
Phylos' genetics platform is designed to improve outcomes for all growers by combining uniform, reliable performance within cultivars with a broad and continuously evolving portfolio of genetically and phenotypically distinct hybrids. The company's breeding program integrates large-scale field data, modern breeding techniques, and rapid iteration to deliver improvements in yield, predictability, disease resistance, and production efficiency.
For more information:
Phylos 
www.phylos.bio
